Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation combo aims to tame prostate cancer with fewer side effects

NCT ID NCT01596816

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to give radiation to men with intermediate-risk prostate cancer. After standard radiation to the prostate and nearby glands, a precise, high-dose boost was added to the tumor. The goal was to improve cancer control while keeping side effects on the bladder and rectum low. 76 men took part, and researchers tracked their urinary and rectal function over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

76 people

The number who actually took part.

Started

Aug 2010

Finished

Sep 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prostate adenocarcinoma proved by histology * With at least one of this intermediate-risk criterias: * T2b * and/or PSA between 10 et 20 ng/ml * and/or Gleason score = 7 * Prostatic volume ≤ 80 cc * No adenopathy(lymph node \< 1.5 cm on scanner or MRI and/or in lymph node dissection) * No metastasis (bone scan) * Age \>= 18 ans * No prior pelvic irradiation * No prior anticancer treatment (prostatectomy, chemotherapy, hormonotherapy \> 3 months) * Performance status (ECOG) \< 1 * No contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation * Life expectancy \>= 10 weeks * Patient affiliated to health insurance * Informed consent signed by the patient Exclusion Criteria: * Cancer no histologically proved * Unfavorable-risk(T2c and/or PSA \> 20 ng/ml and/or Gleason \> 7) * Favorable-risk(T1c T2a and PSA \< 10 ng/ml and Gleason \< 7) * T3 and T4 * History of cancer uncontrolled and/or treated since less of 5 years (except basal cell carcinoma of the skin) * Contraindication to MRI * IPSS score \> 10 * Recurrent or metastatic disease * Allergy to gold * Patient already included in another therapeutic trial with an experimental molecule * Unable for medical follow-up (geographic, social or mental reasons)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54500, France

  • Centre Georges François Leclerc

    Dijon, 21079, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar LAMBRET

    Lille, 59020, France

  • Centre Paul Papin

    Angers, 49933, France

  • Val d'Aurelle-Paul Lamarque

    Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.